Vera Therapeutics initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is bullish on the stock heading into Phase 3 Origin results in IgAN expected in Q2 as well as over the long-term with an anticipated atacicept commercial launch in 2026, the analyst tells investors in a research note. Although povetacicept has a potential market advantage with its more convenient dosing regimen, it will be challenging to demonstrate better results as atacicept has already proven to stabilize eGFR over a long period of time, Wolfe added.